Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Top Democrat, in letter, blasts Valeant CEO for lack of cooperation

Published 2016-04-12, 12:48 p/m
© Reuters.  Top Democrat, in letter, blasts Valeant CEO for lack of cooperation
PSON
-
BHC
-

WASHINGTON, April 12 (Reuters) - A top Democrat in the U.S.
House of Representatives on Tuesday called on Valeant
Pharmaceuticals International Inc VRX.TO for more details on
its relationship with Philidor RX services and chided the
company for not providing Congress any documents or other
requested information.
"Your refusal to cooperate fully with Congress is extremely
troubling and reflects a pattern of obstruction that impairs our
ability to protect the American people against your company's
exorbitant price increases," U.S. Representative Elijah Cummings
wrote in a letter to Valeant Chief Executive Michael Pearson (LON:PSON).

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
U.S. Representative Cummings' letter to Valeant: http://democrats.oversight.house.gov/sites/democrats.oversight.house.gov/files/documents/2016-04-12.EEC
to Pearson re Prescription Drug Prices.pdf
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.